Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Innovent Biologics ( (HK:1801) ) has shared an update.
Innovent Biologics, Inc. successfully held its Annual General Meeting on June 25, 2025, where all proposed resolutions were passed by shareholders. Key resolutions included the re-election of directors, authorization of board remuneration, re-appointment of auditors, and granting of mandates for share buybacks and issuances. The approval of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational stability.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of high-quality medicines. The company is listed on the Hong Kong Stock Exchange and is committed to advancing innovative therapies to address unmet medical needs.
Average Trading Volume: 26,498,634
Technical Sentiment Signal: Buy
Current Market Cap: HK$130.3B
See more insights into 1801 stock on TipRanks’ Stock Analysis page.